The ATB-Raisin antibiotic (ATB) usage monitoring system contributes to the appropriate use of antibiotics. Its objectives are to enable each healthcare facility (HCF) to describe and analyze its antibiotic usage in comparison with a comparable group and to cross-reference this data with bacterial resistance data. Systemic ATBs in class J01 of the Anatomical Therapeutic Chemical (ATC) classification, rifampicin and oral imidazoles, as well as systemic antifungals in class J02, dispensed during inpatient stays, were expressed in terms of defined daily doses (DDD) and reported according to national and World Health Organization recommendations (ATC-DDD system, 2013). Resistance data were collected for seven bacteria/antibiotic pairs. The 1,488 participating healthcare facilities in 2013 accounted for 68% of hospital days and had consumed 377 DDDs per 1,000 hospital days (HD). The most commonly used antibiotics were the amoxicillin-clavulanic acid combination (31%), amoxicillin (17%), and ceftriaxone (6%). Median antibiotic consumption ranged from 49 DDD/1,000 HD in psychiatric hospitals to 650 in military training hospitals. Variations were observed across specialties, ranging from 58 DDD/1,000 HD in psychiatry to 1,568 in intensive care. In the 518 healthcare establishments that have participated every year since 2008, consumption has been stable since 2011 (+0.6%), whereas it had increased by approximately 7% between 2008 and 2011. Resistance data were consistent with those from specific networks. Antifungal consumption was slightly higher in hematology (207 DDD/1,000 patient-days) than in intensive care (168 DDD/1,000 patient-days). Network-based surveillance allows each healthcare facility to assess its position relative to others, exchange information on practices and organizational structures, and track evolving trends. The analysis of antibiotic consumption should be supplemented by an evaluation of practices.